Acacia goes on patent-buying binge; MonoSol carries on with BioDelivery patent claim;

> Acacia Research Corp. ($ACTG) has purchased 13 patents for inhaler drug delivery technology from an unnamed company, the Newport Beach, CA Company has disclosed. Release

> MonoSol RX says it will continue to defend its patent claim against BioDelivery Sciences concerning the use of film drug delivery, despite a recent setback at the U.S. Patent Office. Release

> Discovery Laboratories said a recent clinical trial demonstrated its Afectair ventilator system delivered as much as 70% less nitric oxide to treat newborn infants with pulmonary hypertension compared to standard systems, while still reaching the target dose. Release

> Echo Therapeutics ($ECTE) has raised $5.4 million in direct equity financing. The Philadelphia company is developing the Prelude SkinPrep system for transdermal drug delivery of topical lidocaine and other drugs. Release

> Inovio Pharmaceuticals ($INO), a major of synthetic vaccines, raised a net of $3.7 million in an underwritten public offering to help fuel clinical trial and research expenses. Release

> Spectrum Pharmaceuticals ($SPPI) has filed an investigational new drug application with the FDA for SPI-014, a second-generation lanthanum-based nanoparticle phosphate binding agent designed to treat hyperphosphatemia in patients with end-stage renal disease. Release

> Aphios Corp. in Woburn has secured a U.S. patent involving a more organic way to formulate polymeric microspheres and nanospheres as components for a controlled-release, under the skin or oral delivery drug. Release